Early-stage diabetic kidney disease
Conditions
Interventions
Intervention group:Ursodeoxycholic acid Tablets (Pyrifos) (250mg*24 tablets per box) : 10mg/kg, 2-3 tablets per day, oral. The treatment course is 8 weeks.
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-80 years, both genders. 2. eGFR >=60 ml·min^-1·(1.73 m^2)^-1, and UACR 30-300 mg/g (i.e., G1A2, G2A2). 3. HbA1C <=8.5%. 4. Blood pressure <=130/80 mmHg. 5. The subject (or their legally authorized representative) has signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those with severe primary diseases of the heart, brain, liver and hematopoietic system, etc. 2. Those who have experienced acute metabolic disorders such as diabetic ketoacidosis within the past month; 3. Those with positive HBV serological indicators other than HbsAb and those with abnormal transaminase levels in continuous liver function tests; 4. Participated in other clinical studies within two months prior to the start of the research; 5. Pregnant or lactating women; 6. Patients with confusion, dementia, various mental illnesses and those who are unwilling to cooperate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary microalbumin/urinary creatinine;Renal function (Scr, eGFR);Glycated hemoglobin (HbA1C); | — |
Secondary
| Measure | Time frame |
|---|---|
| Cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL).;Adverse event;Vital signs: body temperature, resting heart rate, blood pressure, etc;Demographic characteristics: gender, age, height, weight; | — |
Countries
China
Contacts
Public ContactLi Ting
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed